From MarketBeat:



The CEO of Alpine Immune Sciences, Inc. sold multiple shares of the stock in December, with the most recent transaction being 2,402 shares at an average price of $20.01. In addition, the company’s stock has been performing well, with a market cap of $1.15 billion. The company also released its quarterly earnings, reporting revenue of $10.04 million despite negative return on equity and net margin. Wall Street analysts have issued positive ratings and price targets for ALPN stock, with an average rating of “Buy” and an average price target of $22.50. Institutional investors have also made changes to their positions in the company, with the majority of the stock being owned by hedge funds. Alpine Immune Sciences is a clinical-stage immunotherapy company that focuses on creating immunotherapies for autoimmune and inflammatory diseases. While the company currently has a “Buy” rating among analysts, there are other stocks recommended by top-rated analysts that are considered better buys.



Original: Insider Selling: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) CEO Sells 2,402 Shares of Stock